# Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

> **NCT01473095** · PHASE1 · COMPLETED · sponsor: **ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)** · enrollment: 120 (actual)

## Conditions studied

- Solid Tumor
- Malignant Lymphoma
- Tumor

## Interventions

- **DRUG:** ARQ 092

## Key facts

- **NCT ID:** NCT01473095
- **Lead sponsor:** ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2017-07-06
- **Final completion:** 2017-08-07
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2017-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01473095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01473095, "Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01473095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*